Does immunotherapy change the treatment paradigm in metastatic gastric cancer?

被引：3

作者：

Camera, Silvia ^{[1
]}

Liscia, Nicole ^{[1
]}

Foti, Silvia ^{[1
]}

Barbieri, Lavinia ^{[2
]}

Cossu, Andrea ^{[2
]}

Puccetti, Francesco ^{[2
]}

Elmore, Ugo ^{[2
]}

Rosati, Riccardo ^{[2
]}

Scartozzi, Mario ^{[3
,4
]}

Mazza, Elena ^{[1
]}

Cascinu, Stefano ^{[1
]}

机构：

[1] Univ Vita Salute San Raffaele, IRCCS San Raffaele Sci Inst, Dept Med Oncol, I-20132 Milan, Italy

[2] Univ Vita Salute San Raffaele, IRCCS San Raffaele Sci Inst, Gastrointestinal Surg Unit, I-20132 Milan, Italy

[3] Univ Hosp, Med Oncol Unit, I-09042 Cagliari, Italy

[4] Univ Cagliari, I-09042 Cagliari, Italy

来源：

MEDICAL ONCOLOGY | 2022年 / 39卷 / 12期

关键词：

Metastatic gastric cancer; Systemic treatment; Immunotherapy; Clinical practice; DOUBLE-BLIND; 1ST-LINE THERAPY; OPEN-LABEL; ADENOCARCINOMA; CAPECITABINE; CHEMOTHERAPY; METAANALYSIS; MONOTHERAPY; PACLITAXEL; CISPLATIN;

D O I：

10.1007/s12032-022-01819-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Gastric cancer represents one of the leading causes of cancer-related death worldwide. Even if the last decade has witnessed an improvement in surgical and systemic treatments, with an increase of overall life expectancy, survival rates still remain unsatisfactory, especially for patients with metastatic disease. Systemic therapies represent the gold standard in the management of stage IV gastric cancer. In this scenario, the availability of effective second and third lines has represented for a long time the only hope to offer an overall survival improvement to these patients. Recently, the advent of immune checkpoint inhibitors has involved also gastric cancer with encouraging efficacy data in the metastatic setting, becoming integral part of the management of selected patients.

引用

页数：9

共 40 条

[1] [Anonymous], SEER CANC STAT SURVI
[2] Impact of body composition, nutritional and inflammatory status on outcome of non-small cell lung cancer patients treated with immunotherapy
Baldessari, Cinzia
Guaitoli, Giorgia
Valoriani, Filippo
Bonacini, Riccardo
Marcheselli, Raffaella
Reverberi, Linda
Pecchi, Annarita
Menozzi, Renata
Torricelli, Pietro
Bertolini, Federica
Barbieri, Fausto
Dominici, Massimo
[J]. CLINICAL NUTRITION ESPEN, 2021, 43 : 64 - 75
[3] Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Bang, Yung-Jue
Van Cutsem, Eric
Feyereislova, Andrea
Chung, Hyun C.
Shen, Lin
Sawaki, Akira
Lordick, Florian
Ohtsu, Atsushi
Omuro, Yasushi
Satoh, Taroh
Aprile, Giuseppe
Kulikov, Evgeny
Hill, Julie
Lehle, Michaela
Ruschoff, Josef
Kang, Yoon-Koo
[J]. LANCET, 2010, 376 (9742) : 687 - 697
[4] Comprehensive molecular characterization of gastric adenocarcinoma
Bass, Adam J.
Thorsson, Vesteinn
Shmulevich, Ilya
Reynolds, Sheila M.
Miller, Michael
Bernard, Brady
Hinoue, Toshinori
Laird, Peter W.
Curtis, Christina
Shen, Hui
Weisenberger, Daniel J.
Schultz, Nikolaus
Shen, Ronglai
Weinhold, Nils
Keiser, David P.
Bowlby, Reanne
Sipahimalani, Payal
Cherniack, Andrew D.
Getz, Gad
Liu, Yingchun
Noble, Michael S.
Pedamallu, Chandra
Sougnez, Carrie
Taylor-Weiner, Amaro
Akbani, Rehan
Lee, Ju-Seog
Liu, Wenbin
Mills, Gordon B.
Yang, Da
Zhang, Wei
Pantazi, Angeliki
Parfenov, Michael
Gulley, Margaret
Piazuelo, M. Blanca
Schneider, Barbara G.
Kim, Jihun
Boussioutas, Alex
Sheth, Margi
Demchok, John A.
Rabkin, Charles S.
Willis, Joseph E.
Ng, Sam
Garman, Katherine
Beer, David G.
Pennathur, Arjun
Raphael, Benjamin J.
Wu, Hsin-Ta
Odze, Robert
Kim, Hark K.
Bowen, Jay
[J]. NATURE, 2014, 513 (7517) : 202 - 209
[5] Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial
Catenacci, Daniel V. T.
Tebbutt, Niall C.
Davidenko, Irina
Murad, Andre M.
Al-Batran, Salah-Eddin
Ilson, David H.
Tjulandin, Sergei
Gotovkin, Evengy
Karaszewska, Boguslawa
Bondarenko, Igor
Tejani, Mohamedtaki A.
Udrea, Anghel A.
Tehfe, Mustapha
De Vita, Ferdinando
Turkington, Cheryl
Tang, Rui
Ang, Agnes
Zhang, Yilong
Hoang, Tien
Sidhu, Roger
Cunningham, David
[J]. LANCET ONCOLOGY, 2017, 18 (11) : 1467 - 1482
[6] Chen LT, 2020, J CLIN ONCOL, V38
[7] First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811
Chung, Hyun Cheol
Bang, Yung-Jue
S Fuchs, Charles
Qin, Shu-Kui
Satoh, Taroh
Shitara, Kohei
Tabernero, Josep
van Cutsem, Eric
Alsina, Maria
Cao, Zhu Alexander
Lu, Jia
Bhagia, Pooja
Shih, Chie-Schin
Janjigian, Yelena Y.
[J]. FUTURE ONCOLOGY, 2021, 17 (05) : 491 - 501
[8] Capecitabine and oxaliplatin for advanced esophagogastric cancer
Cunningham, David
Starling, Naureen
Rao, Sheela
Iveson, Timothy
Nicolson, Marianne
Coxon, Fareeda
Middleton, Gary
Daniel, Francis
Oates, Jacqueline
Norman, Andrew Richard
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (01) : 36 - 46
[9] 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) as a third-line chemotherapy treatment in metastatic gastric cancer, after failure of fluoropyrimidine, platinum, anthracycline, and taxane
Erdem, Gokmen Umut
Bozkaya, Yakup
Ozdemir, Nuriye Yildirim
Demirci, Nebi Serkan
Yazici, Ozan
Zengin, Nurullah
[J]. BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES, 2018, 18 (02) : 170 - 177
[10] Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial
Fuchs, Charles S.
Ozguroglu, Mustafa
Bang, Yung-Jue
Di Bartolomeo, Maria
Mandala, Mario
Ryu, Min-Hee
Fornaro, Lorenzo
Olesinski, Tomasz
Caglevic, Christian
Chung, Hyun C.
Muro, Kei
Van Cutsem, Eric
Elme, Anneli
Thuss-Patience, Peter
Chau, Ian
Ohtsu, Atsushi
Bhagia, Pooja
Wang, Anran
Shih, Chie-Schin
Shitara, Kohei
[J]. GASTRIC CANCER, 2022, 25 (01) : 197 - 206

← 1 2 3 4 →